[go: up one dir, main page]

GB202218585D0 - Antisense oligonucleotides for the treatment of cardiovascular disease - Google Patents

Antisense oligonucleotides for the treatment of cardiovascular disease

Info

Publication number
GB202218585D0
GB202218585D0 GBGB2218585.4A GB202218585A GB202218585D0 GB 202218585 D0 GB202218585 D0 GB 202218585D0 GB 202218585 A GB202218585 A GB 202218585A GB 202218585 D0 GB202218585 D0 GB 202218585D0
Authority
GB
United Kingdom
Prior art keywords
treatment
cardiovascular disease
antisense oligonucleotides
antisense
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2218585.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProQR Therapeutics II BV
Original Assignee
ProQR Therapeutics II BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProQR Therapeutics II BV filed Critical ProQR Therapeutics II BV
Priority to GBGB2218585.4A priority Critical patent/GB202218585D0/en
Publication of GB202218585D0 publication Critical patent/GB202218585D0/en
Priority to EP23822267.3A priority patent/EP4630553A1/en
Priority to AU2023390632A priority patent/AU2023390632A1/en
Priority to KR1020257018248A priority patent/KR20250115388A/en
Priority to CN202380084671.8A priority patent/CN120322556A/en
Priority to PCT/EP2023/084865 priority patent/WO2024121373A1/en
Priority to JP2025531978A priority patent/JP2025540146A/en
Priority to CA3276262A priority patent/CA3276262A1/en
Priority to MX2025006656A priority patent/MX2025006656A/en
Ceased legal-status Critical Current

Links

GBGB2218585.4A 2022-12-09 2022-12-09 Antisense oligonucleotides for the treatment of cardiovascular disease Ceased GB202218585D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB2218585.4A GB202218585D0 (en) 2022-12-09 2022-12-09 Antisense oligonucleotides for the treatment of cardiovascular disease
EP23822267.3A EP4630553A1 (en) 2022-12-09 2023-12-08 Antisense oligonucleotides for the treatment of cardiovascular disease
AU2023390632A AU2023390632A1 (en) 2022-12-09 2023-12-08 Antisense oligonucleotides for the treatment of cardiovascular disease
KR1020257018248A KR20250115388A (en) 2022-12-09 2023-12-08 Antisense oligonucleotides for the treatment of cardiovascular diseases
CN202380084671.8A CN120322556A (en) 2022-12-09 2023-12-08 Antisense oligonucleotides for the treatment of cardiovascular diseases
PCT/EP2023/084865 WO2024121373A1 (en) 2022-12-09 2023-12-08 Antisense oligonucleotides for the treatment of cardiovascular disease
JP2025531978A JP2025540146A (en) 2022-12-09 2023-12-08 Antisense oligonucleotides for the treatment of cardiovascular disease
CA3276262A CA3276262A1 (en) 2022-12-09 2023-12-08 Antisense oligonucleotides for the treatment of cardiovascular disease
MX2025006656A MX2025006656A (en) 2022-12-09 2025-06-06 Antisense oligonucleotides for the treatment of cardiovascular disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2218585.4A GB202218585D0 (en) 2022-12-09 2022-12-09 Antisense oligonucleotides for the treatment of cardiovascular disease

Publications (1)

Publication Number Publication Date
GB202218585D0 true GB202218585D0 (en) 2023-01-25

Family

ID=84974760

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2218585.4A Ceased GB202218585D0 (en) 2022-12-09 2022-12-09 Antisense oligonucleotides for the treatment of cardiovascular disease

Country Status (1)

Country Link
GB (1) GB202218585D0 (en)

Similar Documents

Publication Publication Date Title
AU2023390632A1 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
GB202306756D0 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
GB202218585D0 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
AU2024246572A1 (en) Antisense oligonucleotides for the treatment of liver disease
GB202410081D0 (en) Antisense oligonucleotides for the treatment of cardiovascular disease
GB202306669D0 (en) Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202302381D0 (en) Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202502170D0 (en) Antisense oligonucleotides for the treatment of disease
GB202318087D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202304438D0 (en) Antisense oligonucleotides for the treatment of liver disease
IL319679A (en) Antisense oligonucleotides for the treatment of canavan disease
GB202316851D0 (en) Antisense oligonucleotides for the treatment of moyamoya disease
GB202502333D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202414347D0 (en) Antisense oligonucleotides for the treatment of liver disease
GB202405143D0 (en) Antisense oligonucleotides for the treatment of poly-q disease
GB202313645D0 (en) Antisense oligonucleotides for the treatment of metabolic disorders
GB202400404D0 (en) Antisense oligonucleotides for the treatment of polg-related disorders
GB202418430D0 (en) Antisense oligonucleotides for the treatment of migrane
GB202417415D0 (en) Antisense oligonucleotides for the treatment of metabolic disorders
GB202410747D0 (en) Antisense oligonucleotides for the treatment of metabolic disorders
GB202408796D0 (en) Antisense oligonucleotides for the treatment of metabolic disorders
GB202502460D0 (en) Antisense oligonucleotides for the treatment of cancer
GB202306060D0 (en) Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202217580D0 (en) Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
CA3286425A1 (en) Antisense oligonucleotides for the treatment of liver disease

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)